Wells Fargo & Company Cardiff Oncology, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDF
# of Institutions
98Shares Held
12.8MCall Options Held
823KPut Options Held
78K-
Black Rock Inc. New York, NY2.63MShares$5.81 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$4.72 Million0.0% of portfolio
-
Assenagon Asset Management S.A.1.22MShares$2.69 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA911KShares$2.01 Million0.0% of portfolio
-
State Street Corp Boston, MA805KShares$1.78 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $95.8M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...